No services found
No Products found
When performance matters—such as detecting or quantifying trace amounts of analytes—antibody affinity can make or break your results. Antibodies with ultra-high affinities (10⁻⁹ to 10⁻¹² M) offer better signal-to-noise ratios, allowing you to detect even the smallest quantities of target with confidence and reliability.
Whether you’re detecting or quantifying trace amounts of analytes, affinity is one of the key properties of a successful antibody. At ProteoGenix, we routinely generate antibodies with nanomolar to picomolar affinities. This level of binding strength improves your signal-to-noise ratio, making it easier to detect even the smallest amounts of target — so you can trust your results with full confidence.
This performance-based model is backed by experience from 2000+ successful antibody development projects.
Learn more about the strategy and the results
The No Win – No Fee guarantee applies to a wide range of techniques, including:
Not all projects are the same. That’s why multiple antibody discovery platforms are available to align with your scientific objectives.
Your project is guided by experts with deep scientific backgrounds—PhD-level account managers and seasoned scientists—who help define strategy, interpret results, and keep your development on track.
From ultra-sensitive detection to multiplex assay development, customized antibodies are designed to overcome even the most complex R&D challenges. Examples of successfully delivered projects include:
And this is only a glimpse—any complex requirement can be addressed through tailored strategies and cutting-edge technology. Having a project in mind? Let’s talk!
All antibody development services are 100% royalty-free, with no licensing restrictions or hidden fees. You retain full ownership of the results and can move forward with complete freedom.
At ProteoGenix, we don’t just develop antibodies—we ensure your success. Every project benefits from:
Minimize risk, accelerate timelines, and secure the antibody you need—with performance guaranteed!
We collaborated on a project on generating a monoclonal antibody that recognizes a one-amino-acid mutation in a cancer-associated cell-surface protein. Although the project was technically challenging, we succeeded in generating a hybridoma clone that produced the desired antibody. In the course of the project, we found additional clones that recognized adjacent epitopes and Proteogenix put forth an effort to perform additional subclonings in order to ensure the delivery of clones that perfectly work. In summary, Proteogenix always strived to ensure maximal quality of the product and customer satisfaction, and the account Manager provided prompt and competent support at any time.
Dr. rer. nat. Rudolf Übelhart, Project Leader, Ulm Institute of Immunology
I contacted ProteoGenix regarding the generation of monoclonal antibodies for the detection of a chemokine. ProteoGenix generated for us multiple monoclonal antibodies to detect the chemokine by ELISA, western blot and to test these antibodies in functional assays. They provided an excellent service, with regular updates, quick response to our queries and an excellent delivery of the product. I recommend their service for their efficacy and professionalism.
Dr. Julie Rayes, Associate Professor, Birmingham University, UK
We contacted ProteoGenix to develop repertoires of specific antibodies against three antigens sharing high homology. As determined by ELISA, ProteoGenix developed several specific antibodies that exhibited no cross-reactivity with the other antigens. We appreciated their proactive approach to increase our chances of success (e.g., performing fusions at their own risks). We are satisfied with the services of the company.
Dr. Galit Denkberg, Vice-President Discovery, Canopy Immuno-Therapeutics, Israel
We are thrilled with the success we’ve achieved through our collaboration with ProteoGenix in developing monoclonal antibodies targeting our protein. The antibodies they produced were not only highly selective but also demonstrated exceptional affinity for our target, significantly advancing our research. ProteoGenix impressed us with their efficiency and speed throughout the process. Their commitment to providing excellent customer service made our experience even better, as they were always available to address our questions and concerns. We highly recommend ProteoGenix to anyone in need of high-quality antibody development.
Verónica Alcolea, Development Manager, Telum Therapeutics, Spain
We requested ProteoGenix’s services for the generation of anti-protein monoclonal antibodies to be used in our research. One antibody turned out to be an extremely good reagent, which received strong interest from Merck-Millipore and was eventually sold as part of a CNRS licence agreement in order to be added to Merck-Millipore’s products catalog. I’m definitely satisfied with ProteoGenix’s services!
Dr. Valérie Doye, Group Leader, Institut Jacques Monod, Paris
Early lung cancer detection antibodies.
Breast cancer diagnostic antibodies.
Commercialized antibodies for advanced research.
PC Maity et al., IGLV3-21*01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling. PNAS 117, (8) 4320-27 (2020). https://doi.org/10.1073/pnas.1913810117
N Yacov et al., MOSPD2 is a therapeutic target for the treatment of CNS inflammation. Clin Exp Imm 201, (2) 105-20 (2020). https://doi.org/10.1111/cei.13448
A Surribas et al., Monoclonal antibody-based immunosensor for the electrochemical detection of chlortoluron herbicide in groundwaters. Biosensors 11, (12) 513 (2021). https://doi.org/10.3390/bios11120513
Timelines vary based on:
Development can range from 6 weeks (simplest cases) to over 21 weeks. A precise estimate will be provided during project discussions.
Costs depend on:
Prices start at $5,000 and can exceed $30,000, depending on these factors. A precise estimate will be provided during project discussions.
We can generate antibodies against small molecules, peptides, soluble or membrane proteins (even in native conformation using nanodisc technology), DNA, RNA, and more.
We can produce antibodies from milligram scale up to several hundred grams. For industrial-scale production, we can connect you with trusted CDMO partners.
Yes! We design, optimize, and manufacture diagnostic kits. We can even provide pilot batches for testing and scale up for commercial production under your brand.
+1 919 234 1277
inquiry-mabs@proteogenix.fr
Contact us
Lets’ get in touch!
Send
Your cart is currently empty.